SCHEMBL7954533

SCHEMBL7954533

O=C(Cc1ccc(F)cc1)Nc1nn(CCO)c2nc(-c3cnn4ccccc34)c(F)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.40
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
PIK3CB P42338 1/20 0.36
JAK2 O60674 3/20 0.36
JAK1 P23458 3/20 0.36
JAK3 P52333 3/20 0.36
ATM Q13315 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CACNA1H O95180 3/20 0.36
CACNA1G O43497 2/20 0.36
CACNA1I Q9P0X4 2/20 0.36
MAPK14 Q16539 1/20 0.35
MET P08581 1/20 0.35
EPHB3 P54753 1/20 0.35
ADORA3 P0DMS8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13099793 0.90 AXL (0.38) AXLKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL8049613 0.89 ATM (0.42) KDM4EALDH1A1SMN1; SMN2HTTPIK3CB
SCHEMBL8037402 0.86 APOBEC3A (0.46) KDM4EALDH1A1SMN1; SMN2NPC1HTT
SCHEMBL7950685 0.85 ALDH1A1 (0.43) KDM4EALDH1A1SMN1; SMN2PIK3CBJAK2
SCHEMBL8043059 0.83 ALDH1A1 (0.39) KDM4EALDH1A1SMN1; SMN2PIK3CBJAK2
SCHEMBL8054923 0.83 RAB9A (0.42) KDM4EALDH1A1SMN1; SMN2NPC1HTT
SCHEMBL8043064 0.83 EGFR (0.41) KDM4EALDH1A1SMN1; SMN2PIK3CBJAK2
SCHEMBL7942597 0.82 CCNT1 (0.40) JAK2JAK1JAK3CASP1HSD17B10
SCHEMBL7950972 0.81 MAPK1 (0.43) AXLKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL13099804 0.81 ADORA3 (0.40) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
WO-2010027114-A1 USE OF PYRAZOLE-PYRIDINE DERIVATIVES AND ITS SALTS FOR TREATING OR REVENTIN OSTEOPOROSIS CHOONGWAE PHARMA CORPORATION (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME MAP3K20, MAP3K3, MAP3K1 AXL 955/4885KDM4E 1683/4885ALDH1A1 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.